A highly accurate breast cancer diagnostic test for effective personalized treatment and assessment of therapy response
Project title: A highly accurate breast cancer diagnostic test for effective personalized treatment and assessment of therapy response
Funding Scheme: EIC Accelerator
Starting date: 01/05/2020
Duration in months: 24
Estimated budget: 3 499 325,00 EUR
Abstract
Breast cancer (BCa) is the most common cancer in women worldwide with 2.1M new cases diagnosed annually, and this number is expected to double in 2030. However, today’s diagnostic tests lack precision and, as a result, many BCa patients are misdiagnosed then treated inaccurately, putting their lives at risk while creating undue problems for families and healthcare systems. MultiplexDX (a leading Slovak biotechnology company) proposes a personalized and precise diagnostic test for early and late stage BCa called Multiplex8+. The test combines two IP-protected, revolutionary and multiplexed cancer diagnostic technologies, visualization (RNA FISH) and RNA sequencing. By combining the two technologies to eliminate misdiagnosis, Multiplex8+ defines a specific BCa barcode that suggests a specific personalized treatment, length of therapy and clarifies how likely will a BCa patient benefit from chemotherapy or not.
There are 2 main objectives of this project: 1. Establish an ISO-15189 accredited laboratory to provide diagnostic services to cancer centers (B2B) and additionally to patients (B2C). A clinical validation on 4 000 tissue samples will be conducted to obtain clinically-based evidence; 2. Build the first successful high-value biotech company in Slovakia. The company has already raised €2,05M in seed investments and grants and started sales of subproducts generating €300k in revenues since 2016. MultiplexDX is operating in the Comenius University Science Park in Bratislava and consists of 17 team members, 5 business and 7 scientific advisors. Our planned accumulated revenues in the first 5 years are €305,3M, generating a net profit of €133,0M and representing a ROI of 10,3. Importantly, Multiplex8+ is supported by the entire oncology value chain (patient associations, cancer centers, hospitals, KOLs, insurance companies, pharma/medtech, clinical laboratories, biobanks, investors, etc.).
RELATED NEWS
March 3, 2023 / We revealed more about the recent development of our modern diagnostic test
February 28, 2023 / MultiplexDX Announces Successful Completion of the EIC Accelerator Multiplex8+
February 9, 2023 / MultiplexDX welcomed the Deputy Prime Minister
January 30, 2023 / MultiplexDX joined the leading health tech expo in the Middle East, Arab Health 2023
January 27, 2023 / We joined a prestigious Cancer Crosslinks 2023 Conference in Oslo
January 24, 2023 / The Prime Minister of the Slovak Republic visits MultiplexDX
December 20, 2022 / We had another distinguished guest from the European Parliament at MultiplexDX
November 10, 2022 / Our team joined the 8th Annual World Cancer Series in Brussels organized by the Economist
October 28, 2022 / We welcomed the Minister of Health of Iceland
October 7, 2022 / We represented the latest findings of our research at conference in Smolenice
December 12, 2019 / MultiplexDX Became a Proud Holder of the EIC Accelerator
October 21, 2019 / MultiplexDX received the best SME instrument phase 2 evaluation score among Slovak companies
February 22, 2019 / Another Horizon 2020 Seal of Excellence for MultiplexDX from European Commission
July 10, 2018 / MultiplexDX Was Awarded Horizon 2020 Seal of Excellence by the European Commission
The project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 946693
About MultiplexDX
MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).
MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.
Find out more about MultiplexDX on Corporate website, Facebook, LinkedIn, Twitter
